Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

906.86 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight
Eli Lilly's Phase 3 trial shows Verzenio improves survival in high-risk early breast cancer, with Q2 revenue up 12% to $1.49 billion. 
Via Benzinga
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock. 
Via The Motley Fool
Topics Economy World Trade
Why Novo Nordisk Stock Tumbled on Tuesday
A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy. 
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Tuesday
The pharma giant advanced a medication that could be extremely competitive in a high-profile segment. 
Via The Motley Fool
Russell 2000 Hits 9-Month Highs, Bitcoin Drops Below $110,000: What's Moving Markets Tuesday?
Investors are watching small caps heat up on an otherwise slow Tuesday morning, with the Russell 2000 climbing 1% and outpacing its larger peers, amid growing bets on a Fed rate cut next month. 
Via Benzinga
Topics Economy
Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study
Via Stocktwits
EchoStar, Energy Fuels, Eli Lilly, Hut 8, Nio: Stocks Making The Biggest Moves Today
Via Stocktwits
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway. 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Rep. Jonathan Jackson Has Bought Up to $390K Worth Of Amazon.com Stock: Here's What You Should Know
 
Via Benzinga
As the Market Rotates, This Healthcare ETF Is Leading the Way
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
Via Stocktwits
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test. 
Via Investor's Business Daily
Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors
Eli Lilly's Phase 3 trial of orforglipron showed significant weight loss, blood sugar control, and improved heart health markers in adults with diabetes. 
Via Benzinga
Viking Therapeutics: What's Next?
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum. 
Via The Motley Fool
The Great Rebalancing: Sector Rotation Signals a Shifting Market Landscape
The stock market is currently undergoing a significant rebalancing act, as investors strategically shift their capital from one sector to another in anticipation of evolving economic conditions. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
When AI Execs Say the Market Looks Bubbly
Market chatter about the frothiness of the AI market seems to be picking up as OpenAI CEO Sam Altman claims that he too sees a bubble forming. 
Via The Motley Fool
Topics Artificial Intelligence
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut. 
Via MarketBeat
Topics ETFs Economy
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
From Immuneering Corporation
Via GlobeNewswire
The S&P 500 Hasn't Yielded This Little Since the Dot-Com Bubble. Here's What Investors Can Do.
Growth stocks are dominating the S&P 500, pushing the index's dividend yield to a 25-year low. 
Via The Motley Fool
Topics ETFs Stocks
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
These companies aren't performing as badly as their stock-market performances this year suggest. 
Via The Motley Fool
The Best Stocks to Invest $50,000 in Right Now
There are four names on this list, but the last one may come as a surprise. 
Via The Motley Fool
Topics Artificial Intelligence
If I Could Only Buy 1 S&P 500 Stock From Each Sector for the Rest of 2025, I'd Go With These 11 Dividend Stocks
Incorporating top stocks from a variety of sectors can be an effective way to balance out an investment portfolio. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
Is the Vanguard Mega Cap ETF the Simplest Way to Invest in the Top S&P 500 Stocks?
Investors looking to double down on mega cap stocks like the "Ten Titans" may want to take a closer look at this low-cost ETF. 
Via The Motley Fool
Topics ETFs Stocks
Warren Buffett Makes a Big Buy
Berkshire Hathaway bought $1.6 billion of United Health stock in Q2. Inflation may be ticking higher after all. 
Via The Motley Fool
Topics Economy
Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity
Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock. 
Via Benzinga
$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Here's Why Shares in Viking Therapeutics Crashed This Week
The phase 2 trial results for its key drug didn't pan out quite as planned. 
Via The Motley Fool
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
There are some reasons to be worried; there are also reasons to be optimistic. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.